RxDoctor Payments Data

Samantha Shepherd

Gerontology · Bentonville, ARNPI 1144334343

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Avanir Pharmaceuticals, Inc. at 45.5% of the total. Reporting peaked in 2022 at $310 and has fallen 76.8% since, to $72 in 2025.

$649in general payments, 2019–2025

Across 38 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$295
  • Urovant Sciences Inc$99
  • Novo Nordisk$86
  • Neurocrine Biosciences, Inc.$55
  • Otsuka America Pharmaceutical, Inc.$51
  • Sumitomo Pharma America, Inc.$47
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$649100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$649 in reported general payments places this provider in the 60th percentile of 89 gerontology providers in Arkansas.

See all gerontology providers in Arkansas

Medicare billing

Part B allowed, 2024
$99,116
Medicare patients
263
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron220$53,507
NuedextaDextromethorphan Hbr/Quinidine57$44,310
EliquisApixaban65$22,179
RexultiBrexpiprazole22$15,950
TrulicityDulaglutide15$12,167
Duloxetine Hcl236$7,995
Divalproex Sodium76$4,150
Mirtazapine60$2,466
Quetiapine Fumarate56$2,454
NovologInsulin Aspart27$2,167
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$2,122
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$2,004
Gabapentin117$1,908
LantusInsulin Glargine,hum.Rec.Anlog23$1,646
Buspirone Hcl42$1,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$47$53,507220 claims
Avanir Pharmaceuticals, Inc.Nuedexta$295$44,31057 claims
Otsuka America Pharmaceutical, Inc.Rexulti$51$15,95022 claims
Novo NordiskNovolog$86$2,16727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 89 gerontology providers in Arkansas.

Other gerontology in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →